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Aims Endothelial progenitor cells (EPC) play a role in endothelium integrity maintenance and regeneration. Decreased
numbers of EPC or their impaired function correlates with an increase in cardiovascular events. Thus, EPC are
important predictors of cardiovascular mortality and morbidity. Microparticles carrying Sonic hedgehog (Shh)
morphogen (MPShhþ) trigger pro-angiogenic responses, both in endothelial cells and in ischaemic rodent models.
Here, we propose that MPShhþ regulates EPC function, thus enhancing vasculogenesis, and correcting the defects in




The mechanisms underlying Shh pathway function and nitric oxide (NO) production in EPC were evaluated.
MPShhþ increased both the in vitro and in vivo vasculogenic capacity of EPC isolated from adult human peripheral
blood samples. MPShhþ treatment significantly increased the expression of Shh signalling pathway genes (PTCH1,
SMO, and GLI1) and masters of pro-angiogenic genes (NOS3, VEGFA, KDR, and KLF2) in EPC. Moreover, MPShhþ in-
creased both the protein expression and activity of eNOS, resulting in increased NO production. Most importantly,
MPShhþ improved the vasculogenic capacity of EPC from AMI patients to levels similar to that of EPC from healthy
patients. All these effects were due to the activation of Shh pathway.
....................................................................................................................................................................................................
Conclusion MPShhþ increase both the vasculogenesis of EPC and their capacity to produce NO, including EPC from patients
who have recently suffered an AMI. This study emphasizes MPShhþ and EPC as potential therapeutic tools for im-
proving vascular regeneration as a treatment for cardiovascular ischaemic disease.
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1. Introduction
Several cardiovascular risk factors can cause endothelial injury and the loss
of endothelium integrity leading to endothelial dysfunction and premature
development of atherosclerotic lesions.1 Endothelial progenitor cells (EPC)
are actively involved in the maintenance and regeneration of endothelial in-
tegrity in health and in ischaemic pathologies such as acute myocardial in-
farction (AMI) and stroke.2,3 EPC are mobilized from the bone marrow
and are recruited by damaged endothelium to re-establish endothelium in-
tegrity.4 Nevertheless, accumulating evidence seems to indicate that fewer
EPC may be available, or that their function might be impaired in the pres-
ence of cardiovascular diseases5 or cardiovascular risk factors.6–8 Thus, it is
likely that in these disease states EPC cannot properly restore endothelium
integrity, subsequently increasing the likelihood of suffering cardiovascular
events.9 Therefore, the development of new therapeutic tools for improv-
ing EPC biology in the cardiovascular pathological setting is imperative.
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Microparticles (MP) are small vesicles measuring 0.1–1mm in diameter
and with a heterogeneous composition that are shed from the plasma
membrane of activated and/or apoptotic cells. In the cardiovascular sys-
tem, MP are mainly produced by endothelial cells, platelets, leucocytes,
erythrocytes, and smooth muscle cells.10 MP may represent a novel
method for promoting intercellular communication as vectors for trans-
porting and delivering biological messages. They can actively participate
in the pathophysiology of organisms, most notably in cardiovascular dis-
eases.11,12 Moreover, because they can deliver secretory molecules such
as cytokines, chemokines, growth factors, and nucleic acids they may be
useful as therapeutic tools for the treatment of different diseases.13
Hedgehog (Hh) signalling pathway plays an essential role in regulating
the morphogenesis of different tissues and organs during development in
species from a wide range of phyla.14 In addition to its role in develop-
ment, Sonic hedgehog morphogen (Shh) has been shown to participate
in cell differentiation, angiogenesis, and proliferation in human adults.15,16
Shh signal transduction is complex and involves three main proteins to
activate the different signalling molecules required to regulate cell prolif-
eration, apoptosis, cytoskeleton organization, angiogenesis, gene tran-
scription and metabolism: Patched 1 (PTCH1), Smoothened (SMO), and
GLI1 family of transcription factors.17,18
Engineered MP generated from T lymphocytes under mitogenic and
apoptotic conditions carry the morphogen Shh (MPShhþ).19 These have
previously been shown to have a beneficial effect on endothelial cells in
an ischaemic murine model, as well as in human-origin cultured endothe-
lial cells by improving endothelial function and favouring angiogene-
sis.20,21 MPShhþ can induce nitric oxide (NO) production and reduce
reactive oxygen species in endothelial cells, further supporting their ben-
eficial effect on the cardiovascular system via a phosphoinositide 3-kinase
(PI3K) pathway-dependent mechanism.22 However, the effect of MPShhþ
on adult human peripheral blood-derived EPC remains to be deter-
mined. Furthermore, whether MPShhþ can correct the impaired function
of EPC obtained from AMI patients has not yet been assessed.
Therefore, the aim of this present study was to test the hypothesis that
MPShhþ regulate EPC function, enhance vasculogenesis, and correct the
defects associated with EPC derived from AMI patients. We also evalu-
ated the mechanisms, which underlie Shh pathway and NO production
in endothelial cells.
2. Methods
Detailed experimental protocols are available in the Supplementary ma-
terial online.
This work conforms to the principles outlined in the Declaration of
Helsinki, was approved by the INCLIVA Clinical Research Ethics
Committee and written informed consent was obtained from all the
donors. Animal studies were carried out using protocols approved by
the Institutional Ethics Committee at the University of Valencia and con-
formed to the National Institutes of Health Guide for the Care and Use
of Laboratory Animals.
2.1 Endothelial progenitor cell isolation,
culture, and characterization
EPC were isolated and cultured as previously described in detail by our
group.23 Briefly, peripheral blood was drawn from patients diagnosed
with AMI (n = 11) and healthy controls (n = 20). Mononuclear cells were
then isolated by density gradient centrifugation and cultured in complete
EGM-2 culture medium supplemented with 20% fetal bovine serum.
After 24 h, non-adherent cells were removed and the remaining isolated
EPC were maintained at 37C with 5% CO2. The endothelial nature of
the cultures were confirmed by testing their ability to uptake acetylated
low density lipoprotein (acLDL), to bind Ulex lectin, and to express Von
Willebrand factor (vWF).
2.2 Microparticle preparation
MP were generated from human lymphoid CEM T cell line, as previously
described.20,22 To produce MPShhþ, cells were treated with phytohae-
magglutinin for 72 h followed by phorbol-12-myristate-13 and actinomy-
cin D for 24 h; MP not harbouring Shh morphogen (MPShh-) were
produced from CEM T cells treated only with actinomycin D for 24 h.
After treatment, the culture supernatant containing the MP were recov-
ered, centrifuged and pelleted in sterile NaCl (0.9% w/v). Finally, MP
were recovered in sterile NaCl (0.9% w/v), adjusting their dilution to
10lg of MP proteins per mL (both for MPShhþ and MPShh-) as the opti-
mal concentration for angiogenesis induction.20,21
2.3 Formation of capillary-like structures
in vitro
EPC isolated from peripheral blood samples were seeded at 1.5 105
cells/well on 24-well plates coated with MatrigelVR and were incubated
for 24 h, either in the presence or in the absence of MPShhþ (10mg/mL)
or MPShh- (10mg/mL). In some experiments, the SMO inhibitor cyclop-
amine (15mM) or PI3K inhibitor LY 294002 (10mM) were added 30 min
before starting the treatment with MP. The desired concentrations of
cyclopamine and LY294002 were obtained by serial dilutions of a stock
solution with DMSO. In all the experiments, control cells were exposed
to 0.1% DMSO to discard any effect of the vehicle. Capillary-like struc-
ture formation was recorded with a Nikon digital sight Ds-QiMc camera
and Nikon Eclipse-Ti inverted microscope with a 4 objective (total
magnification 40). For each experimental condition, five random fields
were selected and analysed with Image Pro-Plus Software V.6. All meas-
urements were conducted by an observer blinded to the experimental-
group assignment.
2.4 In vivo Matrigel plug assay
For in vivo studies of MP-induced EPC vasculogenesis, EPC were incu-
bated in the absence or presence of MPShhþ (10mg/mL) for 24 h in vitro.
Matrigel reagent was supplemented with growth factors contained in
EGM-2 single quots. Matrigel plugs were prepared on ice by mixing
300mL of Matrigel with 7.5 105 EPC, which were or were not pre-
treated with MPShhþ. These plugs were then subcutaneously injected
into each hind flank of nude RjOrl: NMRI-Foxn1nu/Foxn1nu mice under
isoflurane anaesthesia (n = 6 controls, n = 6 MPShhþ, n = 3 cyclopamine,
and n = 6 cyclopamineþMPShhþ). Animal health was monitored daily by
specialized staff; after 7 days the mice were euthanized under isoflurane
anaesthesia and the plugs were removed and homogenized in lysis buffer
overnight at 4C. The total haemoglobin content per plug, referred to its
weight, was determined using Drabkin reagent. All measurements were
conducted by an observer blinded to the experimental-group
assignment.
2.5 Immunohistochemistry of Matrigel
plugs
Frozen Matrigel plug sections (20 lm) were incubated with primary
mouse anti-human CD31 antibody and, following washing steps with
PBS, with rabbit anti-human CD34 antibody. Alexa Fluor 488 goat anti-


































































































mouse or goat anti-rabbit Alexa Fluor 546 secondary antibodies were
used to detect CD31 and CD34 respectively. Nuclei were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI). Confocal microscopy
and digital image recording were used to calculate the vessel area using
ImageJ software (National Institute of Health, USA).
2.6 Quantitative polymerase chain reaction
analysis
To determine the expression of Shh pathway signalling genes as well as
genes of cardiovascular interest in EPC, cells were recovered in TRIzolVR
reagent and total RNA isolation was performed using a PureLinkVR RNA
Mini Kit. For the reverse-transcription reactions, 300 ng of total RNA
was reverse transcribed using a High-Capacity cDNA reverse-
transcription kit. The mRNA levels were determined by quantitative
real-time PCR analysis using an ABI Prism 7900 HT Fast Real-Time PCR
System (Applied Biosystems) and gene-specific primer pairs and probes
with a TaqMan Universal PCR Master Mix. Each sample was analysed in
triplicate and the expression values were calculated according to the
2-DDCt method.
2.7 Determination of nitric oxide
production
NO production in cultured EPC was determined using a 4-amino-
5-methylamino-20,70-difluorofluorescein (DAF-FM diacetate) fluorescent
probe. First, cells were incubated for 24 h, either in the presence or in
the absence of MPShhþ (10mg/mL) or MPShh- (10mg/mL) preincubated
with or without cyclopamine (15mM), LY 294002 (10mM), or the NO
synthase inhibitor Nx-Nitro-L-arginine methyl ester hydrochloride
(L-NAME; 100mM). After treatment, DAF-FM diacetate (3.8mM) was
added to the culture media for 30 minutes. NO production was deter-
mined by measuring DAF-FM fluorescence on a Nikon digital sight Ds-
QiMc camera and Nikon Eclipse-Ti fluorescence inverted microscope
(with a 10 objective; giving a total magnification of 100). For each
experimental condition, five random fields were analysed with Image
Pro-Plus Software V.6 and the mean intensity fluorescence per power
field was recorded.
2.8 Western blot analysis
EPC cultures were incubated for 24 h either in the presence or absence
of MPShhþ (10mg/mL) or MPShh- (10mg/mL) and preincubated with
cyclopamine (15mM) or LY 294002 (10mM) for 30 min or not. The con-
tents of the EPC culture wells were then recovered with RIPA buffer
and the proteins were extracted according to standard protocols. Equal
amounts of protein were separated by polyacrylamide gel electrophore-
sis and transferred to nitrocellulose membranes. Blots were incubated
overnight with adequate antibodies, using b-actin as a loading control,
and subjected to densitometric analysis using MacBiophotonics plug-ins
for ImageJ software.
2.9 Statistical analysis
Data normality was assessed using the Kolmogorov–Smirnov test.
Values shown in the text and figures represent the mean ± the standard
error of the mean (SEM). Statistical analysis was performed either by us-
ing Student’s t-tests for single comparisons or one-way analysis of vari-
ance (ANOVA) for multiple comparisons and the Newman–Keuls post-
test. P-values <0.05 were considered significant. Statistical analysis was
carried out using Prism software (version 5.04; GraphPad Software Inc.,
San Diego, CA, USA).
3. Results
3.1 Endothelial progenitor cell isolation
and characterization
All cell cultures used in the present investigation were cultured and iso-
lated under to the most suitable conditions, as previously determined.23
All EPC cultures took on the familiar cobblestone-like morphology used
to identify endothelial cells in culture (Supplementary material online,
Figure S1A). Similarly, cell cultures employed in these experiments were
able to uptake acLDL and bind Ulex-Lectin—thus, indicating their endo-
thelial cell-like phenotype (Supplementary material online, Figure S1B)—,
and expressed vWF, a multimeric glycoprotein constitutively expressed
in endothelial cells (Supplementary material online, Figure S1C). In addi-
tion, we performed immunophenotyping of these cells by flow cytome-
try (Supplementary material online, Figure S2). Cultured EPC expressed
the endothelial markers KDR, CD31, and CD146, whereas panleukocyte
marker CD45 was absent, and progenitor the marker CD34 was found
in 45% of cells. Collectively, these data demonstrated that cultured EPC
used in the present work were late EPC.
3.2 MPShh1 promote in vitro capillary-like
structure formation and in vivo EPC
vasculogenesis
To test the effect of MPShhþ on EPC function, first we studied its effect
on in vitro vasculogenesis. Untreated EPC and those treated with MPShh-
formed capillary-like structures on Matrigel matrices, but the overall
structures were poorly organized (Figure 1A). In contrast, EPC treated
with MPShhþ for 24 h produced significantly longer capillary-like struc-
tures than non-treated EPC (1691± 123 vs. 835± 67 lm; Figure 1B),
which were more organized.
To assess whether MPShhþ could also increase vasculogenesis in vivo,
we performed Matrigel plug assays. Seven days after subcutaneous im-
plantation, the retrieved plugs contained a blush of blood vessel prolifer-
ation in mice that received EPC pretreated with MPShhþ for 24 h
(Figure 1C). Quantification of the haemoglobin content per plug showed
that MPShhþ-treated EPC plugs exhibited an increase in total haemoglo-
bin content of 1.59 ± 0.27-fold (Figure 1D) compared with the controls.
In the presence of the selective hedgehog signalling inhibitor, cyclop-
amine, the effects of MPShhþ in both macroscopic appearance and hae-
moglobin content were completely abolished.
Next, we stained the Matrigel plugs with anti-human CD31 antibody
to analyse vessel density (green, Figure 1E). The CD31-positive staining
showed a proliferation and reorganization of EPC on Matrigel plugs.
Moreover, the density of mature vascular structures in the MPShhþ-
treated EPC plugs was higher than in untreated EPC (Figure 1F), and this
effect was prevented in the presence of cyclopamine. The staining of
plug samples with CD34 was much less intense (red, Figure 1E) than
CD31, thus reflecting a decreased progenitor capacity which was not
modified by exposure to MPShhþ and/or cyclopamine.
Therefore, these results show that MPShhþ were able to increase the
in vivo vasculogenic capacity of EPC through an Shh-mediated pathway.
3.3 MPShh1 induce Shh signalling pathway
and endothelial gene expression on EPC
To analyse the pathways regulated by MPShhþ in EPC, first we checked
the constitutive expression of the main Shh signalling pathway compo-
nents in EPC. We found that PTCH1, SMO, and GLI1 were basally-
expressed in EPC, but after treatment with MPShhþ for 24 h, their
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Figure 1 The capacity of EPC to form capillary-like structures in vitro and to induce vasculogenesis in vivo. EPC isolated from peripheral blood samples
from healthy patients were incubated for 24 h on a Matrigel matrix, either in the presence or in the absence of 10mg/mL MPShhþ or 10mg/mL MPShh-.
(A) Representative phase-contrast images of capillary-like structures. Scale bars: 100 lm. (B) Quantification of the total length (lm) of capillary structures.
Data are expressed as mean ± SEM (each point is the average of five random fields, n = 6 independent experiments). In another set of experiments, EPC in
culture were treated or without 10mg/mL MPShhþ for 24 h, either in the presence or in the absence of 15lM cyclopamine. After treatment, 7.5 105 EPC
were mixed with 300mL Matrigel reagent and injected subcutaneously into nude RjOrl: NMRI-Foxn1nu/Foxn1nu mice. (C) Representative macroscopic
images of Matrigel plugs, 7 days after subcutaneous injection. (D) Total haemoglobin content per plug (mg haemoglobin/g matrigel), expressed as mean ±
SEM (n = 3–6 plugs). For quantitative analysis of angiogenesis and blood vessel architecture, EPC were visualized with green CD31 and red CD34 immuno-
fluorescence. Nuclei were counterstained with DAPI (blue). (E) Representative images of vascular network formation in the Matrigel plug 7 days after im-
plantation at 100 magnification are shown. (F) The relative quantity of CD31þ (closed symbols) and CD34þ (open symbols) EPC was estimated by
calculating the area occupied by green and red fluorescence (pixels), respectively. Data are the mean values ± SEM (each point is the average of five random
fields, n = 3 independent experiments). *P < 0.05, **P < 0.01, and ***P < 0.001 (one-way ANOVA followed by Newman-Keuls’ test).
























































expression increased by 1.59 ± 0.05, 1.86 ± 0.34, and 2.58 ± 0.16-fold,
respectively. Shh pathway gene expression remained unchanged in EPC
treated with MPShh- (Figure 2A). In terms of genes involved in angiogene-
sis, MPShhþ treatment significantly increased NOS3, VEGFA, KDR, and
KLF2 expression by 2.75 ± 0.87, 2.35 ± 0.47, 1.78± 0.13, and 1.75 ± 0.22-
fold, respectively (Figure 2B). However, the expression of these genes in
MPShh--treated EPC remained similar to that of non-treated EPC. These
results suggest that the Shh signalling pathway is functional in EPC and
can be activated by MPShhþ, leading to increased expression of pro-
angiogenic genes.
3.4 MPShh1 promote in vitro capillary-like
structure formation through Shh signalling
pathway activation
To elucidate whether the Shh carried by MPShhþ produced the increased
capillary structure formation, EPC were incubated either with the selec-
tive hedgehog-signalling inhibitor, cyclopamine, or the PI3K inhibitor, LY
294002. Both these treatments prevented the formation of capillary-like
structures (Figure 3A and B) and compared with MPShhþ alone, cyclop-
amine or LY 294002 reduced the total capillary length by approximately
50%, from 1697± 171lm to 837± 124 and 914± 183lm, respectively.
Addition of the inhibitors without MPShhþ had no effect on EPC
capillary-like structure formation (Figure 3B). These results indicate that
Shh signalling pathway activation and PI3K activity produce the increased
vasculogenic capacity of EPC treated with MPShhþ.
3.5 MPShh1 stimulate NO production
through Shh signalling activation
Because NOS3 expression was increased in our experiments, we studied
the role of the Shh pathway in NO production in EPC exposed to MP.
Treatment with MPShhþ but not MPShh- stimulated NO production in
EPC (Figure 4A and B). In addition, the use of the inhibitors cyclopamine
and LY 294002 completely prevented the MPShhþ-mediated increase in
NO production. As expected, this effect was completely abolished by
the presence of the NO synthase inhibitor, L-NAME (Figure 4C and D).
Furthermore, MPShhþ treatment had no effect on Akt protein expression
nor Akt phosphorylation at its activator site—Ser 473 (Figure 5A).
Interestingly, MPShhþ also significantly increased eNOS protein expres-
sion and phosphorylation at its activator site (Ser 1177), while MPShhþ
treatment reduced eNOS phosphorylation at its inhibitory site (Thr 495;
Figure 5B). Cyclopamine and LY 294002 completely abrogated the effects
of MPShhþ on the NO pathway in EPC, while in the absence of MPShhþ
NO production, protein expression, and Akt and eNOS phosphoryla-
tion were unaffected. These results show that MPShhþ activate a SMO
and PI3K inhibitor-sensitive mechanism, producing heightened NO pro-
duction and increased eNOS protein expression and activity.
3.6 MPShh1-mediated capillary-like
structure formation is NO-independent
To investigate the relationship between NO production and in vitro
capillary-like structure formation, EPC were treated with MPShhþ in the
presence or absence of L-NAME for 24 h. Although L-NAME abolished
the MPShhþ-induced increase in NO production (Figure 4C and D), it did
no affect the increase in the total length of capillary-like structures pro-
duced by MPShhþ (Supplementary material online, Figure S3).
3.7 MPShh1 effect on cultured EPC isolated
from acute myocardial infarction patients
We also cultured EPC isolated from the peripheral blood of patients
who had suffered an AMI and tested whether MPShhþ produces similar
Figure 2 Gene expression in EPC treated with MP. EPC were incubated either in the presence of 10mg/mL MPShhþ or 10mg/mL MPShh- for 24 h.
After treatment, expression of PTCH1, SMO, GLI1, NOS3, VEFG, KDR, and KLF2 was determined by real-time quantitative PCR. (A) Shh signalling pathway
gene expression. (B) Expression of genes of cardiovascular interest. Data are the mean ± SEM (n = 3–5 independent experiments, performed in different cell
cultures). *P < 0.05 and **P < 0.01 (one-way ANOVA followed by Newman-Keuls’ test).
















































..effects in these cells. The demographic and main clinical data of all partici-
pants are presented in Supplementary material online, Table S1. Our
results revealed that EPC isolated from patients that had suffered an
acute AMI had a reduced vasculogenic capacity compared with those
from healthy volunteers (570± 54 vs. 774± 32 lm; Figure 6A and B).
MPShhþ significantly increased the vasculogenic capacity of healthy
donors. Interestingly, MPShhþ also increased the vasculogenic capacity of
EPC derived from AMI patients to similar levels to those from healthy
donors. In fact, the increase in vasculogenic capacity produced by
MPShhþ was indistinguishable between healthy donors (142%) and AMI
patients (158%). The effect of MPShhþ in EPC from healthy donors was
completely abolished in the presence of cyclopamine. The basal EPC ex-
pression of NOS3, VEGFA, KDR, and KLF2 was not modified in AMI
patients (Figure 6C). When cells were exposed to MPShhþ, the expres-
sion of these genes in EPC derived from AMI patients increased to the
same levels as those from healthy donors. Thus, MPShhþ were able to re-
store the vasculogenic capacity of EPC obtained from AMI patients.
4. Discussion
Here, we demonstrate for the first time in human EPC that MP, gener-
ated from T lymphocytes under mitogenic and apoptotic conditions and
carrying the morphogen Shh, induce: (i) in vitro and in vivo vasculogenesis;
(ii) the expression of Shh signalling pathway genes and genes involved in
vasculogenesis; (iii) NO production which is directly mediated both by
the Shh pathway and PI3K activation; and most importantly (iv) MPShhþ
improve the vasculogenic capacity of human EPC isolated from AMI
patients.
EPC are capable of postnatal vasculogenesis so they are a mechanism
for endothelial maintenance and repair because they counteract ongoing
endothelial cell injury, replace dysfunctional endothelia, and enhance tis-
sue repair after ischaemic vascular injury.2,24,25 Among the different EPC
sources, human EPC can be isolated and expanded from peripheral
blood23 making them easily to manipulate in laboratory conditions. Cells
isolated using our protocol23 are likely true late EPC, because, in addition
to their morphologic characterization (Supplementary material online,
Figure S1), they are positive for the expression of endothelial markers
CD31, KDR, CD146, the progenitor marker CD34, and negative for the
expression of the panleukocyte marker CD45 (Supplementary material
online, Figure S2).
Revascularization by autologous patient-derived EPC is a promising
therapeutic strategy for enhancing vascular repair in ischaemic dis-
eases26,27 and represents a significantly expanding field.28 However, we
still lack knowledge of the mechanisms that control EPC function and
how this might be augmented.
The use of MPShhþ is one of the most promising developments in the
field of cardiovascular medicine and regenerative therapy.13,21 Here, we
demonstrate that MPShhþ can improve the vasculogenic capacity of hu-
man EPC in vitro, by increasing both the total length and the apparent in-
tegrity of EPC-derived tube-like structures. Indeed, this effect is
comparable to that found in human endothelial cells cultured in vitro.20
The same study also showed that silencing the Shh receptor PTCH1 and
pharmacological SMO inhibition with cyclopamine abrogated the effects
Figure 3 In vitro EPC capillary-like structure formation and Shh signalling pathways. EPC were incubated either in the presence of 10mg/mL MPShhþ or
10mg/mL MPShh- for 24 h, preincubated or without 15mM cyclopamine or 10mM LY 294002, on a Matrigel matrix. (A) Representative phase-contrast images
of capillary-like structures. Scale bars: 100 lm. (B) Quantification of the total length (lm) of capillary-like structures. Data are the mean ± SEM (each point is
the average of five random fields, n = 4–10 independent experiments). **P < 0.01 and ***P < 0.001 (one-way ANOVA followed by Newman-Keuls’ test).







































of MPShhþ, suggesting that its ability to enhance vasculogenesis might be
mediated by Hh signalling pathway activation. Accordingly, in two differ-
ent endothelial cell models, Shh pathway activation by recombinant Shh
induces cyclopamine-sensitive capillary morphogenesis by rapidly acti-
vating PI3K and transcriptionally-regulated pathways.29
Our results also indicate that the effect of MPShhþ on EPC in vitro is pre-
served in vivo. Nude mice implanted with MPShhþ-treated human EPC
Matrigel plugs develop more capillaries than controls, in a Shh-dependent
manner, thus reinforcing the role that MPShhþ plays in augmenting vasculo-
genesis. MPShhþ were previously found to promote neovascularization
in vivo in a mouse model of hind limb ischaemia by stimulating vascular den-
sity and blood flow recovery in ischaemic limbs after femoral artery liga-
tion.21 Thus, MPShhþ also improves the vasculogenic function of human
EPC isolated from peripheral blood.
In terms of gene expression, our study revealed that PTCH1, SMO, and
GLI1, the main members of the Hh signalling pathway, are basally
expressed in EPC isolated from peripheral blood samples. Moreover,
treating EPC with MPShhþ increase the expression of these genes sug-
gesting activation of the canonical Hh signalling pathway. This concurs
with results from Hh-treated bone marrow-derived EPC and primitive
human haematopoietic cells.30,31 However, HUVEC32 as well as the iso-
lated, expanded, and cultured EPC used in this study respond differently
to Shh. In this sense, it is likely that HUVEC and mature endothelial cells
only activate non-canonical responses upon Shh treatment,32 while EPC
probably activate both canonical and non-canonical responses.
Of note, MPShhþ increase the expression of its receptor, SMO. This
effect was first demonstrated in Drosophila33 but has also been demon-
strated in other experimental models, such as adult motor neurons in
rat axotomy34 and in cell hypoxia,35 suggesting that Shh may stimulate
SMO in an autocrine manner.
In human EPC, MPShhþ induce a cyclopamine-sensitive increase in the
mRNA expression of several genes involved in vasculogenesis and NO
production, including VEGF, KDR, KLF2, and eNOS. This indicates that Shh
carried by MP acts on several target genes that regulate vascular function
at different levels. Previous studies show that MPShhþ improve endothe-
lial function in mouse aorta and favors in vitro20 and in vivo angiogenesis21
by increasing NO production through eNOS activity. Surprisingly, inhibi-
tion of NO production with L-NAME does not affect the EPC vasculo-
genic capacity induced by MPShhþ, suggesting that this effect does not
result from MPShhþ-mediated NO production.
Figure 4 NO production induced by MP on EPC. To evaluate the involvement of the Shh signalling pathway in NO production, EPC were incubated in
the presence or absence of 10mg/mL MPShhþ or 10mg/mL MPShh- for 24 h, pre-incubated or without 15mM cyclopamine or 10mM LY 294002. Cells were
then loaded with the fluorescent probe DAF-FM diacetate to determine total NO-production. (A) Representative fluorescence images of NO production
by treated EPC. Scale bars: 100 lm. (B) Quantification of total NO production relative to the control values, is presented as mean ± SEM (n = 4–10 indepen-
dent experiments, performed in different cell cultures). In another set of experiments, EPC were incubated for 24 h in the presence or absence of 10mg/mL
MPShhþ, pre-incubated or without 100mM of the NO synthase inhibitor L-NAME, and NO production was tested. (C) Representative images of NO pro-
duction by cultured EPC after different treatments. Scale bars: 100 lm. (D) Total NO production quantification, relative to the control values, is expressed
as the mean ± SEM (n = 5 independent experiments, performed in different cell cultures). *P < 0.05, **P < 0.01, and ***P < 0.001 (one-way ANOVA
followed by Newman-Keuls’ test).













































..The use of the selective inhibitors cyclopamine and LY 294002
completely abrogated the increase of EPC vasculogenic capacity in-
duced by MPShhþ, suggesting that this effect is mainly mediated by
mechanisms directly dependent on SMO and PI3K. Our results dem-
onstrate that in EPC, MPShhþ act via Shh signalling pathway activation,
also involving PI3K pathway participation. This mechanism of action is
similar to one previously described for endothelial cells treated either
with MPShhþ20 or with recombinant Shh protein.29 However, the ulti-
mate cause of the increase in EPC vasculogenic capacity may also be
related to increased VEGFA expression. There is in vivo evidence sug-
gesting that the effect of Shh on wound healing is facilitated by in-
creased VEGF-mediated neovascularization and does not only result
from stimulating re-epithelialization.30 More recently, Renault et al.36
have shown that Shh-corneal angiogenesis is mediated by activation
of the SMO and Rho/ROCK pathways but not by the expression of
GLI transcription factors.
MPShh-, MP generated under apoptotic conditions not harbouring Shh
morphogen, have no effect on EPC gene expression, NO production, or
vasculogenesis. However, even though these MP do not contain Shh, we
cannot exclude the possibility that MPShhþ may contain other proteins
not present in MPShh-, and that this could potentially influence or even
potentiate the changes we observed in this study. In fact, MPShhþ can in-
crease the expression of different of proangiogenic factors in endothelial
cells,20,21 and not all of these factors are regulated in a Shh-dependent
manner.21
A recent study demonstrated that blood outgrowth endothelial cells
retain a robust proangiogenic profile with a therapeutic potential for tar-
geting ischaemic disease.37 In other studies, EPC isolated from patients
suffering AMI presented a reduced vasculogenic capacity compared with
those of EPC isolated from healthy patients. This reinforces the evidence
that EPC from AMI patients exhibit altered functional behaviour, as mea-
sured by cell adhesion or calcium influx.38 Interestingly, here we demon-
strate that MPShhþ treatment can be used to improve the vasculogenic
capacity of EPC derived from AMI patients to levels similar to those
found in healthy volunteers, also in a Shh-dependent manner. In that
sense, other authors have recently reported that Shh-modified human
CD34 cells preserved cardiac function after infarction through the
exosome-mediated delivery of Shh.39 Therefore, Shh signalling pathway
activation through MPShhþ treatment may rescue EPC function in culture
and it can potentially be used to promote neovascularization in AMI
patients.
In conclusion, our results indicate that MPShhþ exert a positive ef-
fect on EPC by increasing their vasculogenic and NO production ca-
pacities through the Shh signalling pathway. This effect is maintained
in EPC isolated from human peripheral blood samples of patients
suffering AMI where vasculogenic and NO production capacities are
impaired. Taken together our results are sufficient to propose the
use of MPShhþ and EPC as a potential therapeutic tool for improving
vascular regeneration in patients affected by ischaemic diseases such
as AMI.
Figure 5 Regulation of NO production and the Shh signalling pathway. EPC were incubated in the presence or in the absence of 10mg/mL MPShhþ or
10mg/mL MPShh- for 24 h, pre-incubated or without 15mM cyclopamine or 10mM LY 294002. Representative western blot images and relative levels
assessed by densitometry showing the effect of MP treatment on (A) total Akt and phosphorylation of Akt at Serine 473 (presented as the ratio of total and
phosphorylated protein) and (B) total eNOS expression and phosphorylation of eNOS at Serine 1177 and Threonine 495 (both presented as the ratio of to-
tal and phosphorylated protein). Data are the mean ± SEM (n = 3–7 independent experiments, performed in different cell cultures). *P < 0.05, **P < 0.01,
and ***P < 0.001 (one-way ANOVA followed by Newman-Keuls’ test).
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Figure 6 The effect of MP on EPC isolated from acute myocardial infarction patients. EPC were isolated from peripheral blood samples from healthy
donors (HD) and acute myocardial infarction patients (AMI). EPC were incubated for 24 h either in the presence or in the absence of 10mg/mL MPShhþ, pre-
incubated or without 15mM cyclopamine, on a Matrigel matrix. (A) Representative phase-contrast images of capillary-like structures. (B) Total length quanti-
fication (lm) of capillary structures formed on the Matrigel matrices are the mean ± SEM (each point is the average of five random fields, n = 5–11
independent experiments). (C) After treatment, expression of genes of cardiovascular interest (NOS3, VEFG, KDR, and KLF2) was determined by real-time
quantitative PCR. Data are the mean ± SEM (n = 7–8 independent experiments, performed in different cell cultures). *P < 0.05, **P < 0.01, and ***P < 0.001
(one-way ANOVA followed by Newman-Keuls’ test).
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transfusion of endothelial progenitor cells reduces neointima formation after vascular
injury. Circ Res 2003;93:e17.
5. Dong C, Goldschmidt-Clermont PJ. Endothelial progenitor cells: a promising thera-
peutic alternative for cardiovascular disease. J Interven Cardiology 2007;20:93–99.
6. Krenning G, Dankers PY, Drouven JW, Waanders F, Franssen CF, van Luyn MJ,
Harmsen MC, Popa ER. Endothelial progenitor cell dysfunction in patients with pro-
gressive chronic kidney disease. Am J Physiol Renal Physiol 2009;296:F1314–F1322.
7. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner
GC. Human endothelial progenitor cells from type II diabetics exhibit impaired prolifera-
tion, adhesion, and incorporation into vascular structures. Circulation 2002;106:2781.
8. Imanishi T, Hano T, Sawamura T, Nishio I. Oxidized low-density lipoprotein induces
endothelial progenitor cell senescence, leading to cellular dysfunction. Clin Exp
Pharmacol Physiol 2004;31:407–413.
9. Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial pro-
genitor cells: limitations for therapy? Arterioscler Thromb Vasc Biol 2006;26:257–266.
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